Life Sciences & MOBs Sustain Demand Amidst Market Headwinds
By Majid Radaei, RadCRE · · Industry Insights
Despite broader CRE slowdowns, life sciences and medical office buildings (MOBs) continue to attract significant investment, with transaction volumes remaining robust.
Life Sciences and MOBs: Counter-Cyclical Demand Drivers
The commercial real estate landscape in early 2026 continues to navigate a complex environment of elevated interest rates and tighter lending conditions. However, certain sectors are demonstrating remarkable resilience, with life sciences and medical office buildings (MOBs) at the forefront. These specialized asset classes, buoyed by demographic shifts, technological advancements, and a persistent need for healthcare infrastructure, are attracting substantial investor capital, differentiating themselves from more challenged traditional property types.
Robust Investment Activity and Key Transactions
Investment into the life sciences sector, though down from the record highs of 2021-2022, remains robust due to strong tenant demand and long-term growth prospects. Major players like Blackstone and Brookfield continue to deploy capital strategically. For instance, recent reports indicate that Alexandria Real Estate Equities, a bellwether in the life sciences space, continues to expand its footprint in key innovation clusters. While specific large-scale portfolio transactions in Q1 2026 are still emerging, the sector saw significant venture capital inflows into biotech firms in 2025, which correlates to future lab and R&D space demand. Additionally, institutional investors, such as Starwood Capital Group, are actively seeking opportunities, with their recent acquisition of a portfolio of MOBs in the Southeast U.S. in late 2025 for an undisclosed sum, highlighting continued conviction in the healthcare real estate sector.
Medical office buildings, in particular, are proving to be a safe haven. Yields for MOBs have remained relatively stable compared to other asset classes, often trading at cap rates in the 6.0% to 7.5% range for stabilized, well-located assets with long-term leases to strong healthcare systems. Cushman & Wakefield's Q4 2025 medical office market report highlighted that net absorption remained positive across most major metros, driven by an aging population and the decentralization of healthcare services into outpatient settings. This structural demand underpins investor confidence, leading to strong buyer interest even as lenders exercise greater caution elsewhere.
Financing Landscape for Specialized Assets
While general CRE lending has tightened, life sciences and MOB properties often command more favorable terms from lenders due to their perceived stability and creditworthy tenancy. For high-quality, stabilized MOB assets, all-in debt costs are typically in the SOFR + 250-400 bps range, contingent on leverage and borrower profile. Construction financing, particularly for purpose-built lab facilities, remains more selective but available for experienced developers with pre-leasing commitments. Bridge loans for value-add MOB plays are seen between SOFR + 350-550 bps, reflecting the slightly higher operational risk but still attractive compared to other asset classes.
RadCRE Perspective
"The flight to quality and stability is more evident now than ever, and life sciences and MOBs epitomize that," says Majid Radaei, Founder of RAD Commercial Realty. "We're advising our clients to focus not just on the overall sector, but on the micro-markets within. For life sciences, it's all about access to talent pools and proximity to research institutions – areas like Kendall Square, Biotech Bay, and Research Triangle Park. For MOBs, it’s about strategic alignment with reputable health systems and population growth corridors. While cap rates have softened across the board, the compression we've seen in other sectors is less pronounced here, offering more predictable income streams. We're actively structuring capital stacks for these deals, leveraging relationships with specialized healthcare lenders and private debt funds who truly understand the underlying credit of major health providers. It’s an opportunistic environment for those who can pinpoint the right assets and navigate the nuances of the financing."
Market Outlook
The outlook for life sciences and MOBs remains positive for 2026. The aging American population, coupled with continuous innovation in biotechnology and healthcare delivery, ensures a sustained demand for these specialized real estate types. While capital markets constraints will continue to place pressure on valuations across some sectors, the underlying fundamentals of life sciences and medical office are expected to drive continued strong performance and investor preference.
Tags: life sciences real estate, medical office buildings, CRE investment, RadCRE, commercial real estate financing, capital markets
Sources: CoStar News, Cushman & Wakefield, Commercial Observer, Real Capital Analytics, RadCRE Analysis